Fermentalg has raised US$51 million
Fermentalg has raised US$51 million. US$16 million were raised from its existing shareholders, Demeter, Emertec, and ACE, and US$35 million from news investors, equity funds BPI France, IRDI, Viveris, and Sofiprotéol.
Fermentalg engages in the R&D and production of microalgae by heterotrophic pathway for health, algofuel and aquaculture.
Oaklins’ team in France advised Fermentlag in its fundraising.
Talk to the deal team
Related deals
Bayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn moreVivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn moreSpringwell Veterinary Surgery has been transferred to an Employee Ownership Trust
Springwell Veterinary Surgery has become employee owned after transferring into an Employee Ownership Trust (EOT).
Learn more